In addition, MAPK14, FGF1, FGB, F13A1, and CASR, obtained through the differentia-based approach, also represented potential therapeutic targets for the treatment of CHD and had been confirmed to be related to CHD to some extent [30]. This evidence concerns the gene F13A1 and coronary artery disorder.